There is no simple solution, but more attention must be focused on not only understanding why the suicide prevention programs aren’t working, but also developing dramatically improved detection, prevention, and treatment programs and therapies for soldiers.

As part of this equation, we must continue to examine the link between traumatic brain injuries (TBIs) – including mild TBIs (mTBIs) or concussion – and increased risk for suicide. Of the almost 459,000 service members diagnosed with a TBI worldwide between 2000 and Q1 2022, over 82 percent had concussions.

August 3, 2022 (Boston) – Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, announced today the completion of an interim analysis of its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center.

Oxeia CEO Michael Wyand discusses all things brain injury with host Kim Justus including progress with the development of its clinical stage drug. Oxeia is actively recruiting participants for its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center. OXE103 could advance treatment directly addressing the underlying pathology of mTBI.

Boston, MA, January 20, 2022 ­– Oxeia Biopharmaceuticals, a clinical stage biotech company conducting Phase 2 clinical trials of OXE103 for treating concussion, today announced two new board members and additions to its executive leadership team. The company also announced its corporate headquarters’ move from San Diego to Boston.

BOSTON, MA (December 21, 2021) ­– Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury is actively recruiting participants for its ongoing Phase 2 clinical trial of OXE103 at the University of Kansas Medical Center. OXE103 could advance treatment directly addressing the underlying pathology of concussion (mTBI). The program seeks qualified volunteers from the Kansas City area to participate in this study, which could help people with continued symptoms after sustaining a concussion.

Writing in support of the TBI and PTSD Law Enforcement Training Act, Dr. Michael Wyand, CEO of Oxeia Biopharmaceuticals, calls for adding funding to the bill for finding an effective treatment for concussion.

The Center for Concussion Management at the University of Kansas Health System, in partnership with the University of Kansas Medical Center, is looking for volunteers for a new concussion treatment research study.

If you can’t remove all risk can you at least treat the outcome? This session included a discussion of Oxeia’s concussion drug, OXE103, which is in Phase 2 clinical trials. Click “Read More” to watch the video.

Oxeia Biopharmaceuticals CEO, Dr. Michael Wyand, is participating in One Nucleus BioWednesday Webinar on concussions on Wednesday, July 14, 2021 from 11:00 am to noon Eastern Daylight Time: Prevention vs. Cure – If you can’t remove all risk can you at least treat the outcome? Panelists will discuss current R&D for concussion treatment, new technologies for diagnosing and monitoring concussions and the case for investing in new drugs to treat concussions.

Writing in support of the TBI and PTSD Law Enforcement Training Act, Dr. Michael Wyand, CEO of Oxeia Biopharmaceuticals, calls for adding funding to the bill for finding an effective treatment for concussion.

Oxeia’s Co-founder and Chief Scientific Officer and Director of Trauma Surgery at Scripps Mercy Hospital and free agent defensive back, Richard Sherman say i it’s time for football to approach brain injury with the same zeal it has addressed COVID-19.

Oxeia named a One Nucleus finalist for annual BioNewsRound Award for the company’s announcement of the initiation of Phase 2 trial for its drug treatment for concussion, OXE103. The award, which recognizes life science companies with exciting developments, will be announced at the annual Genesis conference on December 10, 2020.

Dr. Michael Wyand, CEO of Oxeia Biopharmaceuticals and Dr. Chris Nowinski, cofounder and CEO of the Concussion Legacy Foundation, explain why we need to devote more resources to advancing drug research and development for treatment of concussions.

Oxeia CEO Michael Wyand is interviewed by Lindsay Gray of Genetic Engineering and Biotechnology News (GEN) on the company’s Phase 2 clinical trial of OXE103 for treating concussions.